ONCOLYTICS BIOTECH INC
NASDAQ: ONCY (Oncolytics Biotech Inc.)
Last update: 20 minutes ago0.405
-0.02 (-4.91%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Oncolytics Biotech Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.04 |
Select this tab to load the latest available analysis.
|
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.92% |
| % Held by Institutions | 1.53% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sandbox Financial Partners, Llc | 31 Mar 2026 | 400,000 |
| Seeds Investor Llc | 30 Jun 2026 | 258,306 |
| Everhart Financial Group, Inc. | 30 Sep 2026 | 142,341 |
| Doliver Advisors, Lp | 30 Sep 2026 | 100,000 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |